JP2004536128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536128A5 JP2004536128A5 JP2003513583A JP2003513583A JP2004536128A5 JP 2004536128 A5 JP2004536128 A5 JP 2004536128A5 JP 2003513583 A JP2003513583 A JP 2003513583A JP 2003513583 A JP2003513583 A JP 2003513583A JP 2004536128 A5 JP2004536128 A5 JP 2004536128A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- composition
- seq
- sequence number
- peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 229940011871 estrogen Drugs 0.000 claims 3
- 239000000262 estrogen Substances 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 229960001603 tamoxifen Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical group O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2001/017748 WO2003007978A1 (en) | 2001-06-02 | 2001-06-02 | Alpha-fetoprotein peptides and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004536128A JP2004536128A (ja) | 2004-12-02 |
| JP2004536128A5 true JP2004536128A5 (enExample) | 2008-07-03 |
| JP5073154B2 JP5073154B2 (ja) | 2012-11-14 |
Family
ID=21742615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003513583A Expired - Fee Related JP5073154B2 (ja) | 2001-06-02 | 2001-06-02 | α−フェトプロテインペプチドおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1401467B3 (enExample) |
| JP (1) | JP5073154B2 (enExample) |
| AT (1) | ATE494301T1 (enExample) |
| AU (1) | AU2001268133C1 (enExample) |
| CA (1) | CA2449284C (enExample) |
| DE (1) | DE60143818D1 (enExample) |
| WO (1) | WO2003007978A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003044041A2 (en) * | 2001-11-20 | 2003-05-30 | Clf Medical Technology Acceleration Program, Inc. | Alpha-fetoprotein peptides and uses for imaging |
| EP1448593B1 (en) * | 2001-11-20 | 2012-01-11 | Albany Medical College | Alpha-fetoprotein peptides and uses thereof |
| US7943577B2 (en) | 2001-11-20 | 2011-05-17 | Albany Medical College | Alpha-fetoprotein peptides and uses thereof |
| FI118263B (fi) * | 2002-10-09 | 2007-09-14 | Timo Kalevi Korpela | Kaspaasiaktiivisuutta säätelevät peptidit |
| WO2005044982A2 (en) | 2003-09-05 | 2005-05-19 | Oregon Health & Science University | Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
| US20110257096A1 (en) * | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20060111289A1 (en) * | 2004-09-09 | 2006-05-25 | Serometrix, Llc, | Compositions and methods of using Alpha-fetoprotein growth inhibitory peptides |
| EA008926B1 (ru) * | 2004-12-14 | 2007-08-31 | Товарищество С Ограниченной Ответственностью "Реал Мед Компани" | Способ коррекции иммунного состояния организма при анемии |
| US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US20090258865A1 (en) | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| US8440631B2 (en) | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
| PT3415139T (pt) | 2011-06-14 | 2022-06-20 | Neurelis Inc | Administração de benzodiazepina |
| CA3221395A1 (en) | 2021-06-10 | 2022-12-15 | Neurelis, Inc. | Methods and compositions for treating seizure disorders in pediatric patients |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674842A (en) * | 1994-10-26 | 1997-10-07 | Health Research, Incorporated | Growth inhibitory peptide |
-
2001
- 2001-06-02 WO PCT/US2001/017748 patent/WO2003007978A1/en not_active Ceased
- 2001-06-02 AU AU2001268133A patent/AU2001268133C1/en not_active Ceased
- 2001-06-02 DE DE60143818T patent/DE60143818D1/de not_active Expired - Lifetime
- 2001-06-02 CA CA2449284A patent/CA2449284C/en not_active Expired - Fee Related
- 2001-06-02 JP JP2003513583A patent/JP5073154B2/ja not_active Expired - Fee Related
- 2001-06-02 EP EP01946037.7A patent/EP1401467B3/en not_active Expired - Lifetime
- 2001-06-02 AT AT01946037T patent/ATE494301T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516072A5 (enExample) | ||
| JP2009500431A5 (enExample) | ||
| JP2006510571A5 (enExample) | ||
| JP2009521908A5 (enExample) | ||
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| JP2005527470A5 (enExample) | ||
| JP2003501068A5 (enExample) | ||
| ATE479763T1 (de) | Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen | |
| JP2008536483A5 (enExample) | ||
| RU2008105677A (ru) | Усиление действия противораковых агентов | |
| JP2004537581A5 (enExample) | ||
| CY1110941T1 (el) | Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας | |
| DE69531332D1 (de) | Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert | |
| JP2002528060A5 (enExample) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| JP2004531242A5 (enExample) | ||
| CA2692358A1 (en) | Recombinant human interferon-like proteins | |
| JP2006506942A5 (enExample) | ||
| JP2004521123A5 (enExample) | ||
| CA2449284A1 (en) | Alpha-fetoprotein peptides and uses thereof | |
| JP2001526242A5 (enExample) | ||
| TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| DE60326723D1 (de) | Verwendung von zusammensetzungen mit der biologischen aktivität der vasoaktiven intestinalen peptide zur behandlung von sarcoidose | |
| JP2004524323A5 (enExample) |